CHO Cells News and Research

RSS

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences, a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI, the largest genomics organization in the world, announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary genome.

6 Jan 2011

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

27 Dec 2010

Largest genomic study of human medulloblastomas

Medulloblastomas are the most common malignant brain tumors of childhood, with 40 to 50 percent overall mortality. One of the greatest challenges in treating them is that they vary substantially from patient to patient. In the largest genomic study of human medulloblastomas to date, researchers from Children's Hospital Boston, together with collaborators, have identified six subtypes with distinct molecular "fingerprints" that will improve doctors' ability to direct and individualize treatment.

23 Nov 2010

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation's Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing.

19 Nov 2010

MicroAire and Arthrex enter agreement to settle ECTR patent infringement suit

MicroAire Surgical Instruments LLC and Arthrex Inc. announced today that they have entered an agreement to settle a suit accusing Arthrex of patent infringement and breach of contract. At issue was the patented technology that MicroAire owns for minimally invasive treatment of Carpal Tunnel Syndrome.

10 Nov 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

CrystalGenomics to present Phase I MAD study data at Arrowhead Summit

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc. a drug discovery and development biopharmaceutical company, has announced that Dr. William Schmidt, its Vice President of Clinical Development, has been invited to present a talk on Development of CG100649, Tissue-selective Dual Inhibitor of COX-2 and Carbonic Anhydrase for Treatment of Osteoarthritis at Arrowhead's upcoming 4th Annual Pain Therapeutics Summit, to be held on October 4-5, 2010 in Philadelphia.

5 Oct 2010

JustAnswer doctors answer queries on breast cancer

An estimated 207,090 women in the U.S. will be diagnosed with breast cancer this year alone, according to the American Cancer Society. While a diagnosis undoubtedly creates a frightening experience for any family, the more that information is available about the disease, the less upsetting it can be. Naturally, patients will look beyond what is provided by their attending physician, but where can they go when they have specific health questions?

21 Sep 2010

ABC Entertainment, CafePress launch official Dancing with the Stars team t-shirts for Stand Up To Cancer

ABC Entertainment Group and CafePress today announce the launch of official Dancing with the Stars team t-shirts with sales benefiting Stand Up To Cancer.

18 Sep 2010

Sistemic introduces SistemQC services to monitor cells

Sistemic Ltd., the fast growing UK life sciences company, today launched their patented SistemQC services for researchers and industry. SistemQC monitors cells including stem cell populations for intended or unintended change using biologically defined measures. These new product additions will support faster decision making for cell manufacturers at critical QC points within their process workflows.

15 Sep 2010

Life Technologies finalizes cell line license agreement for recombinant protein production

Life Technologies Corporation today announced that it has finalized cell line license agreements with a number of companies to provide rights to Life Technologies' proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines.

14 Sep 2010

Mirus Bio launches new TransIT-PRO transfection kit for biotherapeutic protein production

Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO™ Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection.

19 Aug 2010

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland), an independent, global provider of human proteins for life-threatening diseases.

17 Aug 2010

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Two NJIT biomedical researchers have received the prestigious Coulter Foundation Translational Awards for promising patent applications that may some day extend peoples' lives.The Coulter program provides funding for professors in established biomedical engineering departments within the U.S. Initial funding for each professor will be at least $200,000 over a two-year period.

11 Aug 2010

Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies

Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis, today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS).The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods.

20 Jul 2010

Major biological resource centre increases cell line supply capacity with TAP’s automated cryovial filling system

The Automation Partnership (TAP), world leader in the design and development of innovative automation for life science applications announced its Fill-It™, benchtop automated dispensing system, is being used at one of the world's largest biological resource centres to improve the precision of filling and to significantly reduce the time required to dispense cells into large numbers of cryovials.

6 Jul 2010

New method to synthesize drug candidates for testing

Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group. However, the processes now used require harsh reaction conditions or only work in a small number of cases, limiting their usefulness for synthesizing new drug candidates for testing.

25 Jun 2010

Impact of oil spill on humans and wildlife

University of Rhode Island Pharmacy Professor Bongsup Cho knows there are cancer-causing chemicals in diesel fumes and cigarette smoke.

25 Jun 2010

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the IBC 6th Annual Cell Line Development and Engineering conference held in San Francisco, California from June 21 - 24, 2010.

24 Jun 2010

ASH selects 14 participants for 2010 MMSAP

The American Society of Hematology announces the selection of 14 participants for its 2010 Minority Medical Student Award Program, which encourages minority Medical students to purse an interest in hematology research. Award recipients will each receive the support of a research mentor and a career-development mentor, travel stipends to attend the ASH annual meeting, and a subscription to the scientific journal Blood, the official journal of ASH.

18 Jun 2010